Sunil R. Hingorani

Sunil R. Hingorani

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Sunil R. Hingorani

Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2009 in Science
Verified
Journal Article
Closed access
PDF file
KOKenneth P. Olive
Kenneth P. Olive
MJMichael A. Jacobetz
Michael A. Jacobetz
CDChristian J. Davidson
Christian J. Davidson
AGAarthi Gopinathan
Aarthi Gopinathan
DMDominick McIntyre
Dominick McIntyre
DTDavid A. Tuveson
David A. Tuveson
It's All in the Delivery: Pancreatic cancer is almost universally associated with a poor prognosis, in part because the tumors are resistant to chemotherapeutic drugs. Working with a mouse tumor model that displays many features of the human disease, Olive et al. (p. 1457 , published online 21 May; see the Perspective by Olson and Hanahan ) found that the tumors were poorly vascularized, a factor likely to impede drug delivery. Treatment of the mice with the chemotherapeutic drug gemcitabine in combination with a drug that depletes tumor-associated stromal tissue led to an increase in tumor vasculature, enhanced delivery of gemcitabine, and a delay in disease progression. Thus, drugs targeting the tumor stroma may merit investigation as a way to enhance the efficacy of conventional chemotherapy for pancreatic cancer.

1 May 2005 in Cancer Cell
Verified
Journal Article
Closed access
SHSunil R. Hingorani
Sunil R. Hingorani
LWLifu Wang
Lifu Wang
AMAsha S. Multani
Asha S. Multani
CCChelsea Combs
Chelsea Combs
TDTherese B. Deramaudt
Therese B. Deramaudt
DTDavid A. Tuveson
David A. Tuveson

1 December 2003 in Cancer Cell
Verified
Journal Article
Closed access
SHSunil R. Hingorani
Sunil R. Hingorani
EPEmanuel F. Petricoin
Emanuel F. Petricoin
AMAnirban Maitra
Anirban Maitra
VRVinodh Rajapakse
Vinodh Rajapakse
CKCatrina King
Catrina King
DTDavid A. Tuveson
David A. Tuveson

1 March 2012 in Cancer Cell
Verified
Journal Article
Closed access
PPPaolo Provenzano
Paolo Provenzano
CCCarlos Cuevas
Carlos Cuevas
ACAmy E. Chang
Amy E. Chang
VGVikas K. Goel
Vikas K. Goel
DHDaniel D. Von Hoff
Daniel D. Von Hoff
SHSunil R. Hingorani
Sunil R. Hingorani

1 October 2005 in Cancer Cell
Verified
Journal Article
Closed access
GHGeorgia Hatzivassiliou
Georgia Hatzivassiliou
FZFangping Zhao
Fangping Zhao
DBDaniel E. Bauer
Daniel E. Bauer
CACharalambos Andreadis
Charalambos Andreadis
ASAnthony N. Shaw
Anthony N. Shaw
CTCraig B. Thompson
Craig B. Thompson

1 October 2007 in Cancer Research
Verified
Journal Article
Open access
PDF file
CCCarolyn E. Clark
Carolyn E. Clark
SHSunil R. Hingorani
Sunil R. Hingorani
RMRosemarie Mick
Rosemarie Mick
CCChelsea Combs
Chelsea Combs
DTDavid A. Tuveson
David A. Tuveson
RVRobert H. Vonderheide
Robert H. Vonderheide
Biallelic promoter methylation and transcriptional silencing of the MLH1 gene occurs in the majority of sporadic colorectal cancers exhibiting microsatellite instability due to defective DNA mismatch repair. Long-range epigenetic silencing of contiguous genes has been found on chromosome 2q14 in colorectal cancer. We hypothesized that epigenetic silencing of MLH1 could occur on a regional scale affecting additional genes within 3p22, rather than as a focal event. We studied the levels of CpG island methylation and expression of multiple contiguous genes across a 4 Mb segment of 3p22 including MLH1 in microsatellite-unstable and -stable cancers, and their paired normal colonic mucosa. We found concordant CpG island hypermethylation, H3-K9 dimethylation and transcriptional silencing of MLH1 and multiple flanking genes spanning up to 2.4 Mb in microsatellite-unstable colorectal cancers. This region was interspersed with unmethylated genes, which were also transcriptionally repressed. Expression of both methylated and unmethylated genes was reactivated by methyltransferase and histone deacetylase inhibitors in a microsatellite-unstable colorectal carcinoma cell line. Two genes at the telomeric end of the region were also hypermethylated in microsatellite-stable cancers, adenomas, and at low levels in normal colonic mucosa from older individuals. Thus, the cluster of genes flanking MLH1 that was specifically methylated in the microsatellite-unstable group of cancers extended across 1.1 Mb. Our results show that coordinate epigenetic silencing extends across a large chromosomal region encompassing MLH1 in microsatellite-unstable colorectal cancers. Simultaneous epigenetic silencing of this cluster of 3p22 genes may contribute to the development or progression of this type of cancer. [Cancer Res 2007;67(19):9107–16]